Corpus Intelligence IC Memo — YORK HOSPITAL 2026-04-26 03:44 UTC
IC Memo — YORK HOSPITAL
Investment Committee Memorandum | PA | 533 beds | Grade B | EBITDA uplift $108.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

YORK HOSPITAL

CCN 390046 | YORK, PA | 533 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

YORK HOSPITAL is a 533-bed large academic medical center in YORK, PA with $1.47B in net patient revenue and a 9.7% operating margin. The hospital serves a payer mix of 25.9% Medicare, 1.5% Medicaid, and 72.5% commercial.

Thesis: Platform Growth. Our ML models identify $108.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 9.7% to 17.1% (+736bps).

Net Revenue HCRIS$1.47B
Current EBITDA COMPUTED$143.2M
Operating Margin COMPUTED9.7%
Occupancy HCRIS77.3%
Revenue / Bed COMPUTED$2.8M
Net-to-Gross HCRIS36.5%
Distress Probability ML41.0%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
34
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 9.7% places it above the state median. Among 34 size-comparable peers (266-1066 beds), the median margin is -7.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (266-1066), prioritizing same-state peers. 34 hospitals in the comp set.

HospitalStateBedsRevenueMargin
YORK HOSPITAL (Target)PA533$1.47B9.7%
ST. LUKES HOSPITALPA633$8.94B87.9%
HOSPITAL OF THE UNIV OF PENNAPA1051$3.36B-12.8%
THE CHILDRENS HOSPITAL OF PHILPA667$2.70B-26.8%
MILTON S. HERSHEY MEDICAL CENTPA616$2.08B-2.8%
TEMPLE UNIVERSITY HOSPITALPA761$1.99B0.8%
THOMAS JEFFERSON UNIV. HOSPITAPA868$1.93B-23.1%
GEISINGER MEDICAL CENTERPA525$1.58B4.1%
LANCASTER GENERAL HOSPITALPA620$1.33B-2.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $108.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$30.9M+210bp18mo
Cost to Collect4.5%2.5%$29.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$29.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$17.9M+122bp9mo
Clean Claim Rate88.0%96.0%$941K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$30.9M
Cost to Collect
$29.4M
Denial Rate Reduction
$29.1M
A/R Days Reduction
$17.9M
Clean Claim Rate
$941K
Total EBITDA Uplift$108.2M
Current EBITDA$143.2M
+ RCM Uplift+$108.2M
Pro Forma EBITDA$251.4M
Current Margin9.7%
Pro Forma Margin17.1%
WC Released (1x)$56.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$220.3M$2.03B9.20x55.9%
Base (11x exit)10.0x11.0x$220.3M$2.30B10.44x59.9%
Bull Case9.0x11.0x$198.3M$2.73B13.77x69.0%
Bull (12x exit)9.0x12.0x$198.3M$3.04B15.31x72.6%
Bear Case11.0x10.0x$242.4M$1.41B5.84x42.3%
Bear (11x exit)11.0x11.0x$242.4M$1.63B6.74x46.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 34 hospitals with 266-1066 beds
  • Same-state prioritization (n=35)
  • Comp margins: P25=-19.2% / P50=-7.6% / P75=-1.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.